Sequoia Financial Advisors LLC Sells 10,990 Shares of Bruker Corporation (NASDAQ:BRKR)

Sequoia Financial Advisors LLC lowered its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 27.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,609 shares of the medical research company's stock after selling 10,990 shares during the period. Sequoia Financial Advisors LLC's holdings in Bruker were worth $1,194,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BRKR. Pinnacle Bancorp Inc. acquired a new stake in Bruker during the first quarter worth about $29,000. Wealthquest Corp bought a new stake in shares of Bruker during the 1st quarter worth $143,000. Lecap Asset Management Ltd. acquired a new stake in Bruker in the first quarter valued at about $2,714,000. Rakuten Securities Inc. bought a new position in Bruker in the first quarter valued at about $167,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in Bruker by 81.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 29,826 shares of the medical research company's stock valued at $1,245,000 after acquiring an additional 13,367 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Insider Buying and Selling

In other news, CEO Frank H. Laukien purchased 2,608 shares of the stock in a transaction on Friday, June 6th. The stock was purchased at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the acquisition, the chief executive officer owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 27.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BRKR has been the topic of a number of research analyst reports. UBS Group reduced their price target on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Citigroup downgraded shares of Bruker from a "strong-buy" rating to a "hold" rating and dropped their price objective for the company from $50.00 to $40.00 in a research note on Thursday, May 22nd. Stifel Nicolaus decreased their target price on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Bank of America lowered their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Finally, The Goldman Sachs Group cut their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $52.89.

Bruker Trading Up 1.3%

Shares of NASDAQ:BRKR traded up $0.56 during mid-day trading on Wednesday, reaching $42.46. 2,021,692 shares of the company's stock were exchanged, compared to its average volume of 1,706,077. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57. Bruker Corporation has a twelve month low of $34.10 and a twelve month high of $72.94. The firm has a market capitalization of $6.43 billion, a price-to-earnings ratio of 81.65, a PEG ratio of 2.81 and a beta of 1.18. The business's fifty day moving average price is $38.81 and its 200-day moving average price is $46.24.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.46 by $0.01. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The firm had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. During the same period in the previous year, the business earned $0.53 EPS. The business's quarterly revenue was up 11.0% compared to the same quarter last year. On average, research analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date was Monday, June 16th. Bruker's dividend payout ratio is currently 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.